René Hänsel
SEEK ID: https://ldh.zks.uni-leipzig.de/people/12
Locations:
Germany
, 
United Kingdom
ORCID:
https://orcid.org/0000-0001-8344-0658
Joined: 11th May 2023
Expertise: Not specified
Tools: Not specified
Roles
Admin
Their tagsRelated items
For each clinical trial conducted according to the German Medicines Act (AMG) or the Medical Devices Act (MPG), a sponsor must be named who assumes overall responsibility for the clinical trial. In the case of human clinical trials initiated and managed by staff of the Medical Faculty of the University of Leipzig or Leipzig University Hospital (UKL) (Investigator Initiated Trials; IITs), the University of Leipzig assumes the function of sponsor if no third party is the sponsor.
Trial Projects:
- STOP-NUC: A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response
- BASALIT: Birch Associated Soy Allergy and Immuno-Therapy
- ADIPO-Vent: Optimierung der perioperativen maschinellen Ventilation bei adipösen und normalgewichtigen Patienten durch PEEP-Titration anhand der Elektrischen Impedanz-Tomografie
- GRAFT: Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure
- AbCD: Antibody diagnostics in paediatric Coeliac Disease
- TIBICO: Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients
Coordinating investigator: Prof. Dr. Florian van Bömmel Sektion Hepatologie, Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Sponsor: Universität Leipzig Ritterstr. 26, 04109 Leipzig Registration: EudraCT: 2013-004882-15 DRKS: DRKS00006240
Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg -negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved. Discontinuation of NUC treatment ...
Sponsor: Leipzig University (Sponsor)
Public web page: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004882-15/DE
Start date: 18th Nov 2014
End date: 30th Jan 2022
A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen r Bet v1-FV on Bet v 1 associated soy allergy (Birch Associated Soy Allergy and Immuno-Therapy)
Coordinating investigators: Prof. Dr. Jan C. Simon Prof. Dr. Regina Treudler Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig ...
Sponsor: Leipzig University (Sponsor)
Public web page: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011737-27/DE
End date: 18th Jul 2014
